Literature DB >> 12901589

RNA-transfected dendritic cells.

Smita Nair1, David Boczkowski.   

Abstract

Based on their unique ability to stimulate primary immune responses, dendritic cells are the most potent antigen-presenting cells known. This ability stems from the fact that they are very efficient at the uptake and processing of antigen and they express high levels of major histocompatibility complex class I and class II, as well as costimulatory molecules, which are required to prime naive cytotoxic T-cells. Many groups of investigators have tried to take advantage of these features by developing dendritic cell-based vaccines against tumors and infectious diseases. While the basic principle in these studies is the same--dendritic cells pulsed with antigen are used to elicit cytotoxic T-cell responses--the methods used are varied. This is particularly true with respect to the nature of the antigen used and the method of antigen delivery. In this article, we will focus on the use of RNA as a form of antigen with which to load dendritic cells. We will discuss the rationale behind using RNA as an antigen source and will review recent studies in both murine and human settings that use RNA-pulsed dendritic cells as vaccines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12901589     DOI: 10.1586/14760584.1.4.507

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  6 in total

1.  Analysis of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-reactive CD8(+) T cell responses in children with NPM-ALK(+) anaplastic large cell lymphoma.

Authors:  V K Singh; S Werner; H Hackstein; V Lennerz; A Reiter; T Wölfel; C Damm-Welk; W Woessmann
Journal:  Clin Exp Immunol       Date:  2016-08-16       Impact factor: 4.330

2.  Comparative analysis of cytotoxic T lymphocyte response induced by dendritic cells loaded with hepatocellular carcinoma -derived RNA or cell lysate.

Authors:  Ke Pan; Jing-jing Zhao; Hui Wang; Jian-jun Li; Xiao-ting Liang; Jian-cong Sun; Yi-bing Chen; Hai-qing Ma; Qing Liu; Jian-chuan Xia
Journal:  Int J Biol Sci       Date:  2010-10-13       Impact factor: 6.580

3.  Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer.

Authors:  Claudia M Dollins; Smita Nair; David Boczkowski; Jaewoo Lee; Juliana M Layzer; Eli Gilboa; Bruce A Sullenger
Journal:  Chem Biol       Date:  2008-07-21

4.  NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma.

Authors:  Vijay Kumar Singh; Sebastian Werner; Simone Schwalm; Volker Lennerz; Stephanie Ruf; Serena Stadler; Holger Hackstein; Alfred Reiter; Thomas Wölfel; Christine Damm-Welk; Wilhelm Woessmann
Journal:  Oncoimmunology       Date:  2019-06-26       Impact factor: 8.110

5.  Antigen-presenting cells transfected with Hsp65 messenger RNA fail to treat experimental tuberculosis.

Authors:  C D Rocha; A P F Trombone; J C C Lorenzi; L P Almeida; A F Gembre; E Padilha; S G Ramos; C L Silva; A A M Coelho-Castelo
Journal:  Braz J Med Biol Res       Date:  2012-09-18       Impact factor: 2.590

6.  Immunological targeting of cytomegalovirus for glioblastoma therapy.

Authors:  Smita K Nair; John H Sampson; Duane A Mitchell
Journal:  Oncoimmunology       Date:  2014-06-25       Impact factor: 8.110

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.